REDACTED COPY COLLABORATION AND LICENSE AGREEMENT by and betweenCollaboration and License Agreement • October 5th, 2006 • Trubion Pharmaceuticals, Inc • Pharmaceutical preparations • New York
Exhibit 10.19 RESEARCH COLLABORATION AND LICENSE AGREEMENT This Research Collaboration And License Agreement (the "Agreement") is made by and between The R. W. Johnson Pharmaceutical Research Institute, a division of Ortho-McNeil Pharmaceutical, Inc.,...Collaboration and License Agreement • October 25th, 2000 • Dendreon Corp • Pharmaceutical preparations • California
RECITALSCollaboration and License Agreement • January 27th, 2004 • Cytokinetics Inc
COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • April 11th, 2018 • MorphoSys AG • Pharmaceutical preparations • New York
This COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of June 27, 2010 (the “Effective Date”) by and between XENCOR, INC., a Delaware corporation with its principal offices at 111 West Lemon Avenue, Monrovia, CA 91016 (“Xencor”), and MORPHOSYS AG, a German corporation with its principal offices at Lena-Christ-Strasse 48, 82152 Martinsried/Planegg, Germany (“MorphoSys”).
EX-10.17 21 d564688dex1017.htm EX-10.17 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. RESEARCH COLLABORATION AND LICENSE AGREEMENT by and between ARVINAS, INC. and...Collaboration and License Agreement • May 5th, 2020 • Delaware
This Agreement (this “Agreement”) is effective as of December 22, 2017 (the “Effective Date”), and is entered into by and between Arvinas, Inc., a corporation organized and existing under the laws of Delaware, located at 5 Science Park, 395 Winchester Ave., New Haven, CT 06511 (“Arvinas”) and Pfizer Inc., a corporation organized and existing under the laws of Delaware, located at 235 East 42nd Street, New York, NY 10017 (“Pfizer”).
COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • November 5th, 2020 • CytomX Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) is made and entered into as of May 23, 2014 (the “Execution Date”) by and between CYTOMX THERAPEUTICS, INC., a corporation organized under the laws of the State of Delaware, having its principal place of business at 343 Oyster Point Blvd., Suite 100, South San Francisco, CA, 94080-1913 (“CytomX”), and BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation headquartered at 345 Park Avenue, New York, New York, USA 10154 (“BMS”). CytomX and BMS are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • February 21st, 2018 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • New York
This COLLABORATION AND LICENSE AGREEMENT (“Agreement”) is entered into as of June 18, 2014 (“Effective Date”) by and between Dimension Therapeutics, Inc., a corporation organized under the laws of the State of Delaware, with offices at 1 Main Street, 13th Floor, Cambridge, MA 02142 (“Dimension”), and Bayer HealthCare LLC, a limited liability company organized under the laws of the State of Delaware, with offices at 455 Mission Bay Blvd South, San Francisco, CA 94158 (“Bayer”). Dimension and Bayer are hereinafter referred to individually as a “Party” and collectively as the “Parties.”
Master Collaboration and License Agreement by and between MODERNA THERAPEUTICS, INC. and MERCK SHARP & DOHME CORP. January 12, 2015Collaboration and License Agreement • November 9th, 2018 • Moderna, Inc. • Biological products, (no disgnostic substances) • New York
This Master Collaboration and License Agreement (this “Agreement”), dated as of January 12, 2015 (the “Effective Date”), is made by and between Moderna Therapeutics, Inc., a corporation organized and existing under the laws of Delaware (“Moderna”), and Merck Sharp & Dohme Corp., a corporation organized and existing under the laws of New Jersey (“Merck”). Each of Moderna and Merck may be referred to herein as a “Party” or together as the “Parties”.
COLLABORATION AND LICENSE AGREEMENT BY AND BETWEEN HOMOLOGY MEDICINES, INC. AND NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. DATED NOVEMBER 6, 2017Collaboration and License Agreement • March 23rd, 2018 • Homology Medicines, Inc. • Pharmaceutical preparations • New York
THIS COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is entered into this 6th day of November, 2017 (the “Effective Date”), by and between Homology Medicines, Inc., a corporation organized under the laws of the State of Delaware, having a business address at 45 Wiggins Avenue, Bedford, MA 01730 (“HMI”), and Novartis Institutes for BioMedical Research, Inc., a corporation organized under the laws of the State of Delaware, having a business address at 250 Massachusetts Avenue, Cambridge, MA 02139 (“NVS”). HMI and NVS are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
1 EXHIBIT 10.66 GENE THERAPY COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • July 10th, 1998 • Human Genome Sciences Inc • In vitro & in vivo diagnostic substances • Delaware
BACKGROUNDCollaboration and License Agreement • September 2nd, 2005 • SGX Pharmaceuticals, Inc. • Delaware
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. COLLABORATION AND...Collaboration and License Agreement • November 9th, 2021 • Editas Medicine, Inc. • Biological products, (no disgnostic substances)
This COLLABORATION AND LICENSE AGREEMENT (this “Agreement”), effective as of May 26, 2015 (the “Effective Date”), is made by and between Editas Medicine, Inc., a Delaware corporation, having a principal place of business at 300 Third Street, First Floor, Cambridge, MA 02142 (“Editas”), and Juno Therapeutics, Inc., a Delaware corporation, having a place of business at 307 Westlake Avenue North, Suite 300, Seattle, WA 98109 (“Juno”).
COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • August 6th, 2013 • Intrexon Corp • Services-commercial physical & biological research • Delaware
THIS COLLABORATION AND LICENSE AGREEMENT (this “Agreement”), effective as of June 6, 2011 (the “Effective Date”) is entered into between HALOZYME, INC., a California corporation (“Halozyme”) and INTREXON CORPORATION, a Virginia corporation (“Intrexon”).
Collaboration and License Agreement between ADC Therapeutics Sarl and Genmab A/SCollaboration and License Agreement • April 24th, 2020 • ADC Therapeutics SA • Pharmaceutical preparations • New York
This Collaboration and License Agreement (“Agreement”) is made and entered into, effective as of 14 June 2013 (“Effective Date”), by and between ADC Therapeutics Sarl, a Swiss corporation, having its head office at Rue Saint-Pierre 2, Lausanne, 1003, Switzerland (“ADCT”), and Genmab A/S, a Danish corporation, having its principal place of business at [**] (“Genmab”). Genmab and ADCT are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDMENT to COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • April 24th, 2020 • ADC Therapeutics SA • Pharmaceutical preparations
This Amendment to the Collaboration and License Agreement dated 14 June 2013 between Genmab A/S (“Genmab”) and ADC Therapeutics Sarl (“ADCT”) (hereinafter referred to as the “Agreement”) is entered into with effect from 20 November 2013 by and between Genmab and ADCT (together referred to as “Parties”). All capitalized terms below are as defined in the Agreement.
EX-10.29 7 d665316dex1029.htm EX-10.29 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities...Collaboration and License Agreement • May 5th, 2020
This COLLABORATION AND LICENSE AGREEMENT (“Agreement”) is entered into as of 16 December 2013 (the “Effective Date”) between ACELRX PHARMACEUTICALS, INC., a company organized under the laws of the State of Delaware, United States (“AcelRx”), and having a principal place of business at 575 Chesapeake Drive, Redwood City, CA 94063, United States, and GRÜNENTHAL GMBH, a company organized under the laws of Germany (“Grünenthal”), having its registered office at Zieglerstrasse 6, 52078 Aachen, Germany.
ContractCollaboration and License Agreement • May 5th, 2020 • New York
EX-10.3 2 exel20160331exhibit103-ame.htm EXHIBIT 10.3 CONFIDENTIAL EXHIBIT 10.3 EXECUTION VERSION [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. COLLABORATION AND LICENSE AGREEMENT THIS COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) is entered into as of February 29, 2016 (the “Effective Date”), by and between Exelixis, Inc., a Delaware company having an address at 210 East Grand Avenue, South San Francisco, CA 94080, USA (“Exelixis”) and Ipsen Pharma SAS, a French corporation having an address at 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France (“Licensee”). Exelixis and Licensee may be referred to herein individually as a “Party” or collectively as the “Parties”. RECITALS WHEREAS, Exelixis, a biopharmaceutical company, is developing its proprietary compound known as caboza
COLLABORATION AND LICENSE AGREEMENT by and between KYOWA HAKKO KIRIN CO., LTD. and ULTRAGENYX PHARMACEUTICAL INC. Dated August 29, 2013Collaboration and License Agreement • December 23rd, 2013 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • New York
This Collaboration and License Agreement (this “Agreement”) is made effective as of August 29, 2013 (the “Effective Date”), by and between Kyowa Hakko Kirin Co., Ltd., a company organized and existing under the laws of Japan, with an address at 1-6-1 Ohtemachi, Chiyoda-ku, Tokyo, 100-8185, Japan (“KHK”), and Ultragenyx Pharmaceutical Inc., a company organized and existing under the laws of California, U.S.A., with an address at 60 Leveroni Ct. Novato, CA 94949, U.S.A. (“UGNX”). KHK and UGNX are sometimes hereinafter referred to each as a “Party” and collectively as the “Parties.”
REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. COLLABORATION AND LICENSE AGREEMENT dated byCollaboration and License Agreement • July 31st, 2020 • CureVac B.V. • Pharmaceutical preparations
This COLLABORATION AND LICENSE AGREEMENT (“Agreement”) is effective as of the 19th of December, 2019 (“Effective Date”) and is entered into by and between:
BETWEENCollaboration and License Agreement • April 10th, 2000 • Genome Therapeutics Corp • In vitro & in vivo diagnostic substances • Massachusetts
AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT among CELGENE RIVOT LTD., CELGENE CORPORATION and EPIZYME, INC.Collaboration and License Agreement • August 6th, 2015 • Epizyme, Inc. • Pharmaceutical preparations • New York
This AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) is entered into and made effective as of the 8th day of July, 2015 (the “Effective Date”) among Epizyme, Inc., a Delaware corporation having its principal place of business at 400 Technology Square, 4th Floor, Cambridge, Massachusetts 02139, U.S.A. (“EPIZYME”), Celgene RIVOT Ltd., having its principal place of business at Clarendon House, 2 Church Street Hamilton, HM 11 Bermuda (“CELGENE”), and, solely for the purposes set forth in Section 13.21, Celgene Corporation, a Delaware corporation having its principal place of business at 86 Morris Avenue, Summit, New Jersey 07901 (“PARENT”). EPIZYME and CELGENE are each referred to herein by name or as a “Party” or, collectively, as the “Parties.”
AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT by and between EDITAS MEDICINE, INC. AND JUNO THERAPEUTICS, INC. May 3, 2018Collaboration and License Agreement • August 7th, 2018 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • New York
This AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT (this “Agreement”), effective as of May 3, 2018 (the “Amendment Date”), is made by and between Editas Medicine, Inc., a Delaware corporation, having a principal place of business at 11 Hurley St, Cambridge, MA 02141 (“Editas”), and Juno Therapeutics, Inc., a Delaware corporation, having a place of business at 400 Dexter Avenue North, Suite 1200, Seattle, WA 98109 (“Juno”) and amends and restates that certain Collaboration and License Agreement by and between Editas and Juno (the “Original Agreement”) dated as of May 26, 2015 (the “Original Agreement Effective Date”).
EX-10.46 8 d681079dex1046.htm EX-10.46 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under Execution Version AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT FOR THE UNITED...Collaboration and License Agreement • May 5th, 2020 • New York
THIS AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT FOR THE UNITED STATES (the “Agreement”) is made and entered into as of November 18, 2013 (the “Amended and Restated Execution Date”), by and between POZEN INC., a Delaware corporation having offices at 1414 Raleigh Road, Suite 400, Chapel Hill, North Carolina (“POZEN”), and ASTRAZENECA AB, a Swedish corporation having an office at SE-431 83, Mölndal, Sweden (“Licensee”). POZEN and Licensee each may be referred to herein individually as a “Party,” or collectively as the “Parties.”
EX-10.324 3 dex10324.htm COLLABORATION AND LICENSE AGREEMENT * CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. COLLABORATION...Collaboration and License Agreement • May 5th, 2020 • New Jersey
This COLLABORATION AND LICENSE AGREEMENT (the “Agreement”), dated as of the latest date of signature appearing below (the “Execution Date”) and to be effective as of the Effective Date (as defined below), is made by and among: Pharmacopeia, Inc., a Delaware corporation having its principal place of business at 3000 Eastpark Boulevard, Cranbury, New Jersey 08512, (hereinafter referred to as “Pharmacopeia”); and Schering-Plough Ltd., a Swiss corporation having its principal place of business at Toepferstrasse 5, CH 6004 Lucerne, Switzerland, (hereinafter referred to as “SPL”). Pharmacopeia and SPL are sometimes referred to herein individually as a Party and collectively as the Parties. References to “SPL” and “Pharmacopeia” shall include their respective Affiliates (as hereinafter defined).
COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • August 9th, 2023 • Equillium, Inc. • Pharmaceutical preparations • New York
THIS COLLABORATION AND LICENSE AGREEMENT (“Agreement”) is made and entered into effective as of May 22, 2017 (the “Effective Date”), by and between EQUILLIUM, INC., a corporation organized under the laws of the State of Delaware, USA, with its principal office at 2223 Avenida de la Playa, Suite 108, La Jolla, California 92037, USA (“Equillium”), and BIOCON SA, a company organized under the laws of Switzerland with its principal place of business at c/o BDO SA, Rue De l’Avenir 2, 2800 Delemont, Switzerland (“Biocon”).
EX-10.28 11 d255425dex1028.htm COLLABORATION AND LICENSE AGREEMENT BETWEEN THE REGISTRANT AND SANOFI CONFIDENTIAL COLLABORATION AND LICENSE AGREEMENT by and between Rib-X Pharmaceuticals, Inc. and Sanofi Effective as of June 28, 2011Collaboration and License Agreement • May 5th, 2020 • New York
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.
Enanta has requested that portions of this document be accorded confidential treatment pursuant to Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended. COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • February 5th, 2013 • Enanta Pharmaceuticals Inc • Pharmaceutical preparations • Massachusetts
This COLLABORATION AND LICENSE AGREEMENT (“Agreement”) is made as of February 16, 2012 (“Effective Date”), by and between Novartis Institutes for BioMedical Research, Inc., with its principal office at 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (“Novartis”) and Enanta Pharmaceuticals, Inc., with its principal office at 500 Arsenal Street, Watertown, Massachusetts 02472 (“Enanta”). Novartis and Enanta are each referred to individually as a “Party” and together as the “Parties.”
EX-10.21 3 w20549a5exv10w21.htm EX-10.21Collaboration and License Agreement • May 5th, 2020 • New York
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. COLLABORATION AND LICENSE AGREEMENT THIS COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) is made as of October 29, 2004, by and between Sucampo Pharmaceuticals, Inc., a corporation organized under the laws of Delaware, having its principal place of business at 4733 Bethesda Avenue, Suite 450, Bethesda, Maryland 20814 USA (“SPI”), and Takeda Pharmaceutical Company Limited, a corporation organized under the laws of Japan, having its principal place of business at 1-1 Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, Japan (“Takeda”). SPI and Takeda are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” Recitals WHEREAS, SPI is a United States based pharmaceutical company; and WHEREAS, Takeda is a multinational health care company with research, development and marketing activities in North America through its Affiliates (as h
DEVELOPMENT, COMMERCIALIZATION COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • September 12th, 2012 • Kalobios Pharmaceuticals Inc • Pharmaceutical preparations • New York
REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed.Collaboration and License Agreement • April 28th, 2022 • CureVac N.V. • Pharmaceutical preparations
Section Page 1. Interpretation 3 2. Effective Date 4 3. Amendment and Restatement 4 4. Representations and Warranties 4 5. General Provisions 4 Schedule 1. Amended and Restated 2020 CLA 7
COLLABORATION AND LICENSE AGREEMENT BY AND BETWEEN ABGENIX, INC. AND ASTRAZENECA UK LTD DATED AS OF OCTOBER 15, 2003Collaboration and License Agreement • July 22nd, 2004 • Abgenix Inc • Biological products, (no disgnostic substances) • New York
This COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) dated as of October 15, 2003, is entered into by and between, on the one hand, ABGENIX, INC., a Delaware corporation (“ABX”), having a place of business at 6701 Kaiser Drive, Fremont, California 94555, U.S.A., and, on the other hand, ASTRAZENECA UK LTD., a company incorporated in England under no. 3674842 whose registered office is at 15 Stanhope Gate, London, WIK 1LN, England (“AZ”).
COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • April 3rd, 2014 • Kinemed Inc • Services-commercial physical & biological research • Delaware
This COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) is effective as of the 12th day of June, 2012 (the “Effective Date”) by and between KineMed, Inc., a Delaware company located at 5980 Horton Street, Suite 470, Emeryville, CA 94608 (“KineMed”) and Glaxo Group Limited, a company organized under the laws of England and Wales, having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 ONN, England (“GSK”). Each of KineMed and GSK may be referred to herein as a “Party” or collectively as the “Parties”.
EX-10.1 2 d890758dex101.htm EX-10.1 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. Execution Version AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT by and...Collaboration and License Agreement • May 5th, 2020 • New York
This AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is entered into and made effective as of the 12th day of March, 2015 (the “Restatement Date”) by and between Epizyme, Inc., a Delaware corporation having its principal place of business at 400 Technology Square, 4th Floor, Cambridge, Massachusetts 02139, U.S.A. (“EPIZYME”), and Eisai Co., Ltd., a Japan corporation, having its principal place of business at Koishikawa 4-6-10, Bunkyo-Ku, Tokyo 112-8088, Japan (“EISAI”). EPIZYME and EISAI are each referred to herein by name or as a “Party” or, collectively, as the “Parties.”
COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • May 29th, 2007 • NovaBay Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of the 29th day of August, 2006 (the “Effective Date”) by and between NovaCal Pharmaceuticals, Inc., a California corporation, having its principal place of business at 5980 Horton Street, Suite 550, Emeryville, California 94608 (“NovaCal”) and Alcon Manufacturing, Ltd., a Texas partnership, having its principal place of business at 6201 S. Freeway, Fort Worth, Texas 76134-2099 (“Alcon”). NovaCal and Alcon are each referred to herein by name or, individually, as a “Party” or, collectively, as “Parties.”
COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • November 4th, 2021 • BICYCLE THERAPEUTICS PLC • Pharmaceutical preparations • New York
This Collaboration and License Agreement (the “Agreement”) is made and entered into effective as of July 9, 2021 (the “Effective Date”) by and between BicycleTx Limited, a company incorporated in England and Wales with a place of business at Building 900, Babraham Research Campus, Cambridge CB22 3AT, UK (“BicycleTx”), and Ionis Pharmaceuticals, Inc., a Delaware corporation with a principal place of business at 2855 Gazelle Court, Carlsbad, California 92010, USA (“Ionis”). BicycleTx and Ionis are referred to herein individually as a “Party” and collectively as the “Parties”.
